GUILLERMO RUIZ IRASTORZA-rekin lankidetzan egindako argitalpenak (27)

2023

  1. Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository

    Arthritis and Rheumatology, Vol. 75, Núm. 8, pp. 1407-1414

  2. Clinical phenotype of postural orthostatic tachycardia associated with anti-adrenergic receptor antibodies

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 120, Núm. 2, pp. 66-73

  3. Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 984-995

2021

  1. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 249-257

  2. Clinical presentation of antiphospholipid syndrome

    Lahita’s Systemic Lupus Erythematosus (Elsevier), pp. 561-574

  3. Pregnancy Control in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Part 1: Infertility, Ovarian Preservation and Preconception Assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER)

    Reumatologia Clinica, Vol. 17, Núm. 2, pp. 61-66

  4. Pregnancy control in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn

    Reumatologia Clinica, Vol. 17, Núm. 4, pp. 183-186

  5. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 125-131

2020

  1. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data

    PLoS ONE, Vol. 15, Núm. 9 September

  2. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus

    Lupus, Vol. 29, Núm. 10, pp. 1155-1167

2019

  1. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus

    Lupus, Vol. 28, Núm. 4, pp. 555-559

  2. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts

    Autoimmunity Reviews, Vol. 18, Núm. 9

2018

  1. Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity

    Lupus, Vol. 27, Núm. 10, pp. 1718-1722

  2. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

    Rheumatology (Oxford, England)

  3. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions

    Current opinion in rheumatology, Vol. 30, Núm. 5, pp. 482-489

  4. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study

    Arthritis Care and Research, Vol. 70, Núm. 4, pp. 582-591

2017

  1. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 826-832

2016

  1. Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?

    Current Rheumatology Reports, Vol. 18, Núm. 5

  2. Rituximab-refractory lupus nephritis successfully treated with belimumab

    Clinical and Experimental Rheumatology

  3. SLE: The changing prognosis

    Lupus, Vol. 25, Núm. 12, pp. 1285-1287